RETINOPATHY OF PREMATURITY DO WE HAVE A COMMON CONSENSUS

AHMED MANSOUR

A.LECTURER OF OPHTHALMOLOGY, AIN SHAMS UNIVERSITY AL MASHREQ EYE CENTER - AL FERDAWS EYE CENTER - AL NASR EYE CENTER

DEFINITION

RETINOPATHY OF PREMATURITY (ROP)

- Vision threatening disease in preterm infants due to abnormal vascular development of the retina
- It occurs in premature babies with low birth weight

DO WE HAVE COMMON CONSENSUS

> Arch Ophthalmol. 1984 Aug;102(8):1130-4. doi: 10.1001/archopht.1984.01040030908011.

An international classification of retinopathy of prematurity. The Committee for the Classification of Retinopathy of Prematurity

> Arch Ophthalmol. 1987 Jul;105(7):906-12.

An international classification of retinopathy of prematurity. II. The classification of retinal

deta Special Article

Clas: July 1, 2005

Pren The International Classification of Retinopathy of

Pren

International Classification of Retinopathy of Prematurity, Third Edition

Classification

≫ Author A

Arch Ophth

Michael F. Chiang, MD, ¹ Graham E. Quinn, MD, MSCE, ² Alistair R. Fielder, FRCP, ³ Susan R. Ostmo, MS, ⁴ R.V. Paul Chan, MD, ⁵ Audina Berrocal, MD, ⁶ Gil Binenbaum, MD, MSCE, ² Michael Blair, MD, ^{7,8} J. Peter Campbell, MD, MPH, ⁴ Antonio Capone, Jr., MD, ⁹ Yi Chen, MD, ¹⁰ Shuan Dai, MD, ¹¹ Anna Ells, MD, ¹² Brian W. Fleck, MD, ¹³ William V. Good, MD, ¹⁴ M. Elizabeth Hartnett, MD, ¹⁵ Gerd Holmstrom, MD, PhD, ¹⁶ Shunji Kusaka, MD, PhD, ¹⁷ Andrés Kychenthal, MD, ¹⁸ Domenico Lepore, MD, ¹⁹ Birgit Lorenz, MD, PhD, ^{20,21} Maria Ana Martinez-Castellanos, MD, ²² Şengül Özdek, MD, ²³ Dupe Ademola-Popoola, MD, ²⁴ James D. Reynolds, MD, ²⁵ Parag K. Shah, MD, ²⁶ Michael Shapiro, MD, ⁷ Andreas Stahl, MD, ²⁷ Cynthia Toth, MD, ²⁸ Anand Vinekar, MD, PhD, ²⁹ Linda Visser, MD, ³⁰ David K. Wallace, MD, MPH, ³¹ Wei-Chi Wu, MD, PhD, ³² Peiquan Zhao, MD, ³³ Andrea Zin, MD, PhD, ³⁴

ICROP III 2021

Critical elements of disease classification

Innovations in ophthalmic imaging

 Novel pharmacologic therapies with unique regression and reactivation features

• Recognition that patterns of ROP in some regions of the world do not fit neatly into the current classification system.

KEEP UPDATED

NOMENCLATURE

Chiang et al · ICROP, 3rd Edition





Figure 1. Schema of right eye (RE) and left eye (LE) showing zone borders and clock hour sectors used to describe the location of vascularization and extent of retinopathy. Solid circles represent borders of zones I through III, and dotted circles represent borders of posterior zone II (2 disc diameters beyond zone I). A hypothetical example of examination findings is shown in LE, representing approximately 3 clock hours of stage 1 disease in zone II (note single line on drawing to document presence of stage 1 disease).

POST ZONE 2

The committee defined a region of 2 DD peripheral to the zone I border as posterior zone II to indicate potentially more worrisome disease than ROP in the more peripheral zone

NOTCH


The committee introduced the term notch to describe an incursion by the ROP lesion of 1 to 2 clock hours along the horizontal meridian into a more posterior zone than the remainder of the retinopathy.



NOTCH

 When present, this should be Recorded by the most posterior zone of retinal vascularization with the TERM "secondary to notch"

 For example, ROP in zone II in most places, but with a temporal notch extending into zone I, should be noted as "zone I secondary to notch" thereby distinguishing it from an eye in which most disease is present in zone I.



"STAGE 1, ZONE 1 SECONDARY TO NOTCH, NO PLUS"

PLUS DISEASE

ICROP I 1984: definition of plus disease was introduced


• In the ICROP II 2005: definition of preplus disease was introduced

 In the ICROP III 2021: The committee recommends that the plus disease spectrum be determined from vessels within zone I, rather than from only vessels within the field of narrow-angle photographs and rather than from the number of quadrants of abnormality





Vascular changes, that are not normal, but are insufficient for the diagnosis of plus disease


PLUS DISEASE





PLUS & PRE-PLUS DISEASE RANGE
















CLINICAL PICTURE


STAGE ZERO



Stage 0: incomplete vascularization


Stage 1: Line








Stage 2: Ridge




STAGE 3 VASCULARIZED RIDGE (NEOVASCULARIZATION)







Stage 4a: Partial RD macula on



Stage 4b: Partial RD macula off






Stage 4a: Partial RD macula on


Stage 4b: Partial RD macula off

Stage 5: Total retinal detachment & was classified by configuration of the funnel



When fibrosis precludes visualization of the posterior pole, the extent of detachment must be examined by B-scan ultrasonography.


To permit classification of stage 5 by bedside examination ICROP III committee subclassified stage 5 into 3 subtypes



Stage 5A: Open Funnel RD with visible optic disc



Stage 5B: Closed Funnel RD or Retrolental fibrosis with no visible optic disc yet normal ant segment



Stage 5C: Total RD with anterior segment abnormalities

AGGRESSIVE POSTERIOR ROP (AP-ROP) - AGRESSIVE ROP (A-ROP)

AP-ROP was added to the ICROP II in 2005 to describe a severe, rapidly progressive form of ROP located in zone I or posterior zone II. Previously known as rush disease

AP-ROP as originally described typically affected the very pre- mature infants.

A-ROP VS AP-ROP



AP-ROP

that a continuous spectrum of vascular abnormality exists from normal to plus disease). Updates also include the definition of aggressive ROP to replace aggressive-posterior ROP because of increasing recognition that aggressive disease may occur in larger preterm infants and beyond the posterior retina, particularly in regions of the world with limited resources. ROP regression and reactivation are described in detail, with additional description of long-term sequelae.


ivew vessels in zone z


key challenges and approaches. Subsequently, the entire committee used iterative videoconferences, 2 in-person multiday meetings, and an online message board to develop consensus on classification. *Main Outcome Measures:* Consensus statement.

Results: The ICROP3 retains current definitions such as zone (location of disease), stage (appearance of disease at the avascular—vascular junction), and circumferential extent of disease. Major updates in the ICROP3 include refined classification metrics (e.g., posterior zone II, notch, subcategorization of stage 5, and recognition that a continuous spectrum of vascular abnormality exists from normal to plus disease). Updates also include the definition of aggressive ROP to replace aggressive-posterior ROP because of increasing recognition that aggressive disease may occur in larger preterm infants and beyond the posterior retina, particularly in regions of the world with limited resources. ROP regression and reactivation are described in detail, with additional description of long-term sequelae.


Conclusions: These principles may improve the quality and standardization of ROP care worldwide and may provide a foundation to improve research and clinical care. Ophthalmology 2021;128:e51-e68 Published by Elsevier on behalf of the American Academy of Ophthalmology

APROP-AROP






APROP-AROP



Eyes with A-ROP can demonstrate a unique posterior detachment pattern called Volcano tractional detachment generally involving the fovea, in which the peripheral retina remains attached.





NEW NOMECLATURE

REGRESSION, REACTIVATION, & LONG-TERM SEQUELAE

REGRESSION, REACTIVATION, & LONG-TERM SEQUELAE

Regression: which refers to disease involution and resolution

Reactivation: which refers to recurrence of acute phase features.

 Regression may be <u>complete</u> or <u>incomplete</u> including persistence of retinal abnormalities.

• Regression & reactivation should not be regarded as either the reverse or the repetition of acute ROP.

REGRESSION

Spontaneous or treatment-induced

 Regression tend to occur more rapidly after anti-VEGF therapy (1-3 d) than after laser photocoagulation (7-14 d)

SIGNS OF REGRESSION

Decreased plus disease

Involution of tunica vasculosa lentis


Better pupillary dilation

Greater media clarity

Resolution of intraretinal hemorrhages.



REGRESSION AFTER LASER



REGRESSION AFTER ANTI-VGEF

REGRESSION

PERIPHERAL AVASCULAR RETINA

 Vascularization into the peripheral avascular retina can be complete or incomplete, the latter being termed persistent avascular retina (PAR)

 PAR after ttt with anti-VEGF agents seems to occur with greater frequency and involve a larger retinal area.

REACTIVATION

 Reactivation is seen more frequently after anti-VEGF treatment than after spontaneous regression and rarely if ever occurs after complete laser photocoagulation.

Literature stated that it most commonly occurs between 37 and 60
weeks' PMA. & may occur significantly later, especially if
reinjections are performed.

REACTIVATION SIGNS

 Wide spectrum (new self-limiting demarcation line to reactivated stage 3 with plus disease)

 Vascular changes in ROP reactivation include recurrent vascular dilation, tortuosity, or both or appearance of Nvs

REACTIVATION

 Documentation of reactivation should specify presence and location of new ROP features, noted by zone and stage using the modifier reactivated.

(Example: presence of a demarcation line during reactivation would be noted as "reactivated stage 1.")

• If multiple ridges are present, the modifier reactivated is applied to the more anterior ridge, which is typically more active.

CONCLUSION

 The ICROP III retains current definitions such as zones, stage and circumferential extent of disease.

Major updates in the ICROP3 include

• Def. of posterior zone II, notch, subcategorization of stage 5, and recognition that a continuous spectrum of vascular abnormality exists from normal to plus disease

• Also include the definition of aggressive ROP to replace aggressive-posterior ROP because of increasing recognition that aggressive disease may occur in larger preterm infants and beyond the posterior retina, particularly in regions of the world with limited resources

 ROP regression and reactivation are described in detail, with additional description of longterm sequelae.





RESEARCH Open Access

Analysis of a two-year independent Recogniscreening effort for retinopathy of prematurity in rural Egypt

Sara Tawfik^{1,2}, Ahmed Mansour^{2,3}, Norhan Lotfy Selim^{1,2}, Ahmed M. Habib^{2,3}, Yousef A. Fouad^{2,3*}, Mohamed A. Tawfik^{1,2,4} and Mariam Al-Feky^{2,3,5}

outcome was favorable in 83 eyes (98.8%). Applying the American Academy criteria would have led to the missing of 36.8% of infants with ROP and 28.6% of those requiring treatment in our sample.

world do

ICROP IN NUTSHELL

1. Zone.

- a. Definition of 3 retinal zones centered on the optic disc. The location of the most posterior retinal vascularization or ROP lesion denotes the zone for the eye.
- b. Definition of a posterior zone II region that begins at the margin between zone I and zone II and extends into zone II for 2 disc diameters.*
- c. The term *notch* is used to describe an incursion by the ROP lesion of 1–2 clock hours into a more posterior zone. The ROP zone for such eyes should be noted by the most posterior zone of retinal vascularization with the qualifier "notch" (e.g., "zone I secondary to notch").*
- 2. Plus and Preplus Disease. Plus disease is defined by the appearance of dilation and tortuosity of retinal vessels, and preplus disease is defined by abnormal vascular dilation, tortuosity insufficient for plus disease, or both. Recognition that retinal vascular changes in ROP represent a continuous spectrum from normal to preplus to plus disease, with sample images demonstrating this range.* These changes should be assessed by vessels within zone I, rather than from only vessels within the field of narrow-angle photographs and rather than from the number of quadrants of abnormality.*

- 3. Stage of Acute Disease (Stages 1–3). Stage of acute disease is defined by the appearance of a structure at the vascular—avascular juncture as stage 1 (demarcation line), stage 2 (ridge), and stage 3 (extraretinal neovascular proliferation or flat neovascularization). If more than 1 ROP stage is present, the eye is classified by the most severe stage.
- 4. Aggressive ROP. The term aggressive-posterior ROP was used previously to describe a severe, rapidly progressive form of ROP located in posterior zones I or II. Because of increasing recognition that this may occur beyond the posterior retina and in larger preterm infants, particularly in regions of the world with limited resources, the Committee recommends the new term aggressive ROP.*

ICROP IN NUTSHELL

- 5. Retinal Detachment (Stages 4 and 5).
 - a. Stages of retinal detachment are defined as stage 4 (partial: 4A with fovea attached, 4B with fovea detached) and stage 5 (total).
 - b. Definition of stage 5 subcategories: stage 5A, in which the optic disc is visible by ophthalmoscopy (suggesting open-funnel detachment); stage 5B, in which the optic disc is not visible because of retrolental fibrovascular tissue or closed-funnel detachment; and stage 5C, in which stage 5B is accompanied by anterior segment changes (e.g., marked anterior chamber shallowing, iridocorneolenticular adhesions, corneal opacification), suggesting closed-funnel configuration.* Additional descriptors of funnel configuration (e.g., open-closed) may be applied if clinically useful.
 - 6. Extent of Disease. Defined as 12 sectors in using clock-hour designations.
- 7. Regression. Definition of ROP regression and its sequelae, whether spontaneous or after laser or anti-vascular endothelial growth factor treatment. Regression can be complete or incomplete. Location and extent of peripheral avascular retina (PAR) should be documented.*

- 8. Reactivation. Definition and description of nomenclature representing ROP reactivation after treatment, which may include new ROP lesions and vascular changes. When reactivation of ROP stages occurs, the modifier reactivated (e.g., "reactivated stage 2") is recommended.*
- 9. Long-Term Sequelae. Emphasized beyond previous versions of the ICROP, including sequelae such as late retinal detachments, PAR, macular anomalies, retinal vascular changes, and glaucoma.

ICROP HX

 1984 ICROP I was developed by 23 ophthalmologists from 11 countries.

1987 ICROP I was expanded to include RD

 2005 ICROP II was revisited to incorporate advances during the intervening years including definition of preplus disease
 & AP-ROP

LONG TERM SEQUALEA

Patients with a Hx of premature birth, even without history of ROP, exhibit a spectrum of ocular abnormalities that may lead to permanent sequelae.

- •Late TRD, RRD, or, rarely ERD
- Retinoschisis from chronic traction of involuted stage 3
- Persistent avascular retina. (PAR)
- •PAR is prone to retinal thinning, holes, and lattice- like changes & may be associated with RD later in life.
- Macular anomalies including smaller foveal avascular zone and blunting or absence of the foveal depression
- Retinal vascular changes. persistent tortuosity, straightening of the vascular arcades with macular dragging, and falciform retinal fold.
- •Circumferential interconnecting vascular arcades, and telangiectatic vessels occur frequently.

REGRESSION, REACTIVATION, AND LONG-TERM SEQUELAE

• To date, ROP classification has focused on acute disease, with less attention to regression

 The introduction of anti-VEGF agents has presented new challenges.

 The clinical features and time course of regression after anti-VEGF treatment of ROP differ compared with those of laser-treated

ICROP I: 1984 1987 (UPDATED & EXTENDED)

ICROP II 2005

ICROP III 2021